NMDA Antagonists – New selective compounds to the NR2B subunit with high affinity

The NMDA receptor, an ion channel consisting of four

protein subunits, is involved in the pathophysiology of chronic neurodegenerative diseases, depression, pain and alcoholism. Different subtypes of NMDA receptors can be categorized based on their subunit composition. The NR2B subunit expression is mostly localized in forebrain regions including cortex, hippocampus and striatum. NR2B-selective antagonists have received considerable attention in recent years as they have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. NR2B antagonists bind preferentially to the activated form of the NMDA receptor containing the NR2B subunit and allosterically modulate channel activity by inhibiting channel opening probability. They show advantages over non-selective NMDA receptor antagonists due to greater separation between efficacy and side effects.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work

Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…

New SPECT/CT technique shows impressive biomarker identification

…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…

How 3D printers can give robots a soft touch

Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…

Partners & Sponsors